Roche announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the cobas® SARS-CoV-2 Test. It is intended for the qualitative detection of SARS-CoV-2, the virus that causes COVID-19 disease, in nasopharyngeal and oropharyngeal swab sampl ... more
Roche acquires Stratos Genomics
Further develop DNA based sequencing for diagnostic use
Roche announced that it has acquired Stratos Genomics, an early-stage sequencing technology company to advance the development of Roche’s nanopore sequencer. The acquisition provides Roche access to Stratos Genomics unique chemistry, Sequencing by Expansion (SBX™). The Roche nanopore sequencer, once developed, will utilise a novel approach that combines electronic and biological components to sequence DNA for fast, flexible and cost-effective clinical diagnostic testing.
“Roche is dedicated to creating innovative diagnostics for the most challenging clinical conditions with techniques that are tailored to individual genetic and disease profiles. These solutions address the demands of research and clinical practice to deliver on the promise of personalised healthcare for patients,” said Thomas Schinecker, CEO Roche Diagnostics. “We look forward to further advancing our sequencing technology as we move to the next generation of healthcare and welcome the world-class scientists and employees from Stratos Genomics to Roche.”
The addition of the SBX chemistry, once fully developed, is expected to provide the healthcare community an affordable, fast and flexible result, for multiple targeted clinical applications as well as whole exome and whole genome sequencing.
“We are thrilled to join the Roche family, which will allow us to combine our unique Sequencing by Expansion chemistry with the Roche nanopore sequencer,” said Mark Kokoris, President & CEO at Stratos Genomics. “With our combined expertise and complementary technologies, we are well-positioned to open the path to deliver scalable, high-performance sequencing to clinicians and researchers.”
Stratos Genomics will continue operations in Seattle, Washington, U.S. Financial details of the agreement were not disclosed.
Roche announced it has acquired CAPP Medical, a genomics research company founded by Stanford University oncologists and industry veterans, to advance the development of technology for cancer screening and monitoring through the detection of circulating tumor DNA (ctDNA) in blood. CAPP Med ... more
Roche announced the acquisition of Signature Diagnostics AG, a privately held company based in Potsdam, Germany. Signature is a translational oncology and genomics company that develops large blood plasma and tissue biobanks in multiple cancers, including colorectal and lung, which are cons ... more
- 1analytica 2020: The world’s leading trade fair extends its reach with analytica virtual
- 2analytica 2020: World’s leading trade fair to be held virtually
- 3Sweat for health: Sensor Patches as Fitness Trackers
- 4Leap forward in the fight against antibiotic resistance
- 5Trust in AI but not blindly
- 6Portable, point-of-care COVID-19 test could bypass the lab
- 7Researchers dramatically downsize technology for fingerprinting drugs and other chemicals
- 8New insights into lung tissue in Covid-19 disease
- 9Electron movements in liquid measured in super-slow motion
- 10New 'molecular computers' find the right cells